ADMA Biologics said the FDA approved its supplemental BLA for ASCENIV under section 351(a) of the Public Health Service Act. The approval is a positive regulatory step for the company’s biologics portfolio and supports commercialization of the product. The news is favorable for ADMA but appears incremental rather than market-moving at the sector level.
ADMA Biologics said the FDA approved its supplemental BLA for ASCENIV under section 351(a) of the Public Health Service Act. The approval is a positive regulatory step for the company’s biologics portfolio and supports commercialization of the product. The news is favorable for ADMA but appears incremental rather than market-moving at the sector level.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.42
Ticker Sentiment
